Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

The paper assesses the dose-limiting toxicities and the maximum tolerated dose (MTD) of trastuzumab emtansine (T-DM1) combined with non-pegylated liposomal doxorubicin (NPLD) in HER2-positive (HER2+) metastatic breast cancer (MBC). This single-arm, open-label, phase Ib trial (NCT02562378) enrolled a...

Full description

Bibliographic Details
Main Authors: Elena López-Miranda, José Manuel Pérez-García, Serena Di Cosimo, Etienne Brain, Maja Ravnik, Santiago Escrivá-de-Romaní, Maria Vidal, Joseph Gligorov, Simona Borštnar, Laura Calabuig, Miguel Sampayo-Cordero, Andrea Malfettone, Antonio Llombart-Cussac, Thomas M. Suter, Javier Cortés
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
trastuzumab emtansine
T-DM1
non-pegylated liposomal doxorubicin
HER2-positive
metastatic breast cancer
Online Access:https://www.mdpi.com/2072-6694/12/12/3509

Similar Items

Similar Items